43 results about "Elevated glucose tolerance" patented technology

The invention discloses a function and an application of an RGS6 (regulator of G protein signaling 6) gen in treatment of fatty liver and diabetes mellitus diseases. An RGS6 gene knockout mouse and a wild type C57 mouse are taken as experimental subjects, by means of a high-fat DIO (diet induced obesity) mouse model, a result shows that compared with the wild type C57 mouse, the weight of the RGS6 gene knockout mouse is reduced, the fasting blood-glucose level is lower than that of the WT mouse in a control group, and the liver function is obviously better than that of the WT mouse. An IPGTT (intraperitoneal glucose tolerance test) shows that the glucose tolerance ability of the RGS6 gene knockout mouse is improved obviously. Results of determination in general appearance of the mouse liver, the liver weight, the liver / weight ratio and activity of a liver function related enzyme prove that fatty liver lesions of the RGS6-KO (knockout) mouse in a high fat diet group are relieved obviously, and the lipid accumulation is reduced remarkably. Therefore, the RGS6 can be taken as a target for screening drugs for treating fatty liver and / or T2DM, and an RGS6 inhibitor can be used for preparing the drugs for treating fatty liver and / or T2DM.

The invention discloses a function and use of a DUSP14 gene in treatment on fatty liver and diabetes. DUSP14 knockout mice and wild type C57 mice are as experimental subjects, an obese mouse model induced by high fat diet is used, a test result shows that compared with the wild type C57 mice, DUSP14-KO mice are obese, have fasting blood glucose levels higher than those of the control group WT mice and have liver functions significantly worse than those of the WT mice. An intraperitoneal injection-based glucose tolerance test proves that DUSP14-KO mouse tolerance to glucose is significantly reduced. According to liver weight, a liver / body weight ratio and a lipid pathological staining result, it is shown that the DUSP14-KO mice induced by high fat diet suffer severe fatty liver and fat accumulation is significantly increased. Therefore, DUSP14 can be used as a drug target for screening and treating fatty liver and / or type II diabetes. The accelerator can be used to prepare drugs for treating fatty liver and / or type II diabetes.

The present invention is to present a diagnostic support apparatus for diabetes including a diagnostic support information generating unit which generates diagnostic support information of a patient based on a biological model for reproducing a pseudo-response which simulates a result of a glucose tolerance test for the patient. The biological model comprises a plurality of simulated organ blocks which are configured in such manner that inflow and outflow of glucose and / or inflow and outflow of insulin are reciprocally produced between each of the simulated organ blocks. The plurality of the simulated organ blocks respectively calculate at least one of a cumulative quantity and a concentration of glucose and / or at least one of a cumulative quantity and a concentration of insulin in the respective simulated organ blocks, based on a quantity of inflow and outflow of glucose and / or a quantity of inflow and outflow of insulin in the respective simulated organ blocks.

Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient.